Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H19N2O2 |
Molecular Weight | 223.2915 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 1 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
InChI
InChIKey=ALWKGYPQUAPLQC-UHFFFAOYSA-N
InChI=1S/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1
DescriptionSources: http://www.drugbank.ca/drugs/DB01400Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/neostigmine-methylsulfate-injection.html
Sources: http://www.drugbank.ca/drugs/DB01400
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/neostigmine-methylsulfate-injection.html
Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. By inhibiting acetylcholinesterase, more acetylcholine is available in the synapse, therefore, more of it can bind to the fewer receptors present in myasthenia gravis and can better trigger muscular contraction. Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB01400
Curator's Comment: Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8978837 |
91.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Prostigmin Approved UseNeostigmine is used for:
Treating myasthenia gravis. Launch Date-9.7839363E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
300 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
69.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
79.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/382915/ |
0.07 mg/kg single, intravenous dose: 0.07 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.5 h |
0.03 mg/kg single, intravenous dose: 0.03 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
75% |
0.03 mg/kg single, intravenous dose: 0.03 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NEOSTIGMINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | yes (co-administration study) Comment: information obtained from abstract: AUC of coadministered drug, parathion, parathion was significantly greater than control (65.1 versus 74.3 microg min/ml) Sources: https://pubmed.ncbi.nlm.nih.gov/11913717/ |
PubMed
Title | Date | PubMed |
---|---|---|
Recurarization--fact or fiction. | 1971 Sep-Oct |
|
Antagonism of succinylcholine paralysis in a patient with atypical pseudocholinesterase. | 1972 May |
|
Thioridazine toxicity. Agranulocytosis and hepatitis with encephalopathy. | 1973 Apr 23 |
|
Myasthenia syndrome during penicillamine treatment. | 1975 Jun 28 |
|
Myasthenia associated with D-penicillamine therapy in rheumatoid arthritis. | 1977 |
|
Refractory bradycardia after reversal of muscle relaxant in a diabetic with vagal neuropathy. | 1986 Nov |
|
Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat. | 1987 Mar |
|
Portal hypertension secondary to azathioprine in myasthenia gravis. | 1988 Dec |
|
Impairment of the antagonism of vecuronium-induced paralysis and intra-operative disopyramide administration. | 1989 Jan |
|
Complete heart block following glycopyrronium/neostigmine mixture. | 1989 May |
|
Reversal of antihypertensive agent-induced postural hypotension with physostigmine. | 1991 May-Jun |
|
Intrathecal cholinergic agonists lessen bupivacaine spinal-block-induced hypotension in rats. | 1994 Jul |
|
Interaction between intrathecal neostigmine and epidural clonidine in human volunteers. | 1996 Aug |
|
Spinal neostigmine diminishes, but does not abolish, hypotension from spinal bupivacaine in sheep. | 1996 Nov |
|
Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. | 1997 Jul |
|
Postoperative reparalysis after rocuronium following nebulized epinephrine. | 1997 Mar |
|
Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration. | 1997 Nov |
|
A multi-center study of intrathecal neostigmine for analgesia following vaginal hysterectomy. | 1998 Oct |
|
[Prevention and release of epidural-morphine-induced urinary retention with phenoxybenzamine and neostigmine]. | 2000 Dec |
|
The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines. | 2002 Aug |
|
[Slow channel syndrome due to an autosomal translocation at 2q31-9p27]. | 2002 May |
|
Safety of enteral naloxone and i.v. neostigmine when used to relieve constipation. | 2003 Jun 15 |
|
Cardiac responses of Pacific oyster Crassostrea gigas to agents modulating cholinergic function. | 2004 Dec |
|
Probiotics and functional abdominal bloating. | 2004 Jul |
|
Ciguatera fish poisoning in industrial ship crewmembers: a retrospective study in a seaport general practice in Trinidad and Tobago. | 2004 Sep |
|
[Myasthenia in elderly patients: a series of 23 cases]. | 2005 Dec |
|
Phosphorus-doped and undoped glassy carbon indicator electrodes in controlled-current potentiometric titrations of bromide- or chloride-containing active ingredients in some pharmaceutical preparations. | 2005 Feb 23 |
|
The contribution of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London. | 2005 Jun |
|
A conscious mouse model of gastric ileus using clinically relevant endpoints. | 2005 Jun 6 |
|
Ocular myasthenia gravis and auto-immune thyroiditis in children. | 2005 Nov |
|
Myasthenia gravis accompanied with hypokalemic periodic paralysis. | 2006 May |
|
Neostigmine and pilocarpine attenuated tumour necrosis factor alpha expression and cardiac hypertrophy in the heart with pressure overload. | 2008 Jan |
|
The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease. | 2008 Jul 24 |
|
Prucalopride: the evidence for its use in the treatment of chronic constipation. | 2008 Jun |
|
The effect of piroxicam on the formation of postoperative, intraabdominal adhesion in rats. | 2008 Oct |
|
Interventions for heartburn in pregnancy. | 2008 Oct 8 |
|
Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. | 2008 Sep |
|
Determining the neurotransmitter concentration profile at active synapses. | 2009 Dec |
|
Myasthenia gravis and autoimmune Addison disease in a patient with thymoma. | 2009 Sep |
|
The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions. | 2010 Jun 15 |
|
Efficacy of bupivacaine-neostigmine and bupivacaine-tramadol in caudal block in pediatric inguinal herniorrhaphy. | 2010 Sep |
Patents
Sample Use Guides
The recommended dose range of Neostigmine Methylsulfate Injection is 0.03 mg/kg to 0.07 mg/kg administered as an intravenous bolus.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22178337
In vitro, neostigmine (10⁻⁵ and 10⁻⁴ M) potentiated neurogenic relaxations in the rabbit corpus cavernosum.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N07AA01
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
20
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
FDA ORPHAN DRUG |
388812
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
WHO-ATC |
S01EB06
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
WHO-VATC |
QA03AB93
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
LIVERTOX |
677
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
WHO-ATC |
N07AA51
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
NDF-RT |
N0000175723
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
WHO-VATC |
QN07AA51
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
NCI_THESAURUS |
C47792
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
WHO-VATC |
QN07AA01
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
||
|
WHO-VATC |
QS01EB06
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3982TWQ96G
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
D009388
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
DTXSID1023360
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
4456
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
7315
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB03411MIG
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
NEOSTIGMINE
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
DB01400
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
1897
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
m7819
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | Merck Index | ||
|
3982TWQ96G
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
CHEMBL278020
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
C75024
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
3921
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
59-99-4
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
Neostigmine
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY | |||
|
100000085714
Created by
admin on Fri Dec 15 14:57:45 UTC 2023 , Edited by admin on Fri Dec 15 14:57:45 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)